CBD News
Medical cannabis approved by the European Parliament
On February 13, the European Parliament passed a resolution on the use of cannabis, in particular CBD, for medical purposes, especially for patients undergoing severe treatment.
What does this resolution mean for medical cannabis?
On the initiative of French MEP Guillaume Ballas, member of the Committee on the Environment, Public Health and Food Safety, the European Parliament has passed a resolution encouraging member countries of theEuropean Union to fill the gaps in cannabis research and calls for appropriate training of the medical profession.
Members of the European Parliament highlight the lack of regulation, pointing out that the European Union must ensure the protection of public health, in accordance with Article 168 of the Treaty on the Functioning of the European Union, and are therefore taking action in collaboration with competent international organizations, such as the WHO, which recently recognized CBD as an everyday consumer product.
The resolution also highlights the lack of a clear legal definition of cannabis and its various uses (medical, recreational or industrial), in particular derived products and medicinal products containing medical cannabis already recognized by the European Medicines Agency and certain national authorities such as ANSM in France.
Regarding research, the MEPs note its under-funding and wish to "remove regulatory, financial and cultural obstacles to research on the medical use of cannabis and to cannabis research in general", while defining priority areas by bringing together and coordinating all types of structures (European health organizations, national authorities, patient associations, civil society, social partners, consumer organizations, health professionals, non-governmental organizations).
The European Parliament recognizes that legalizing medical cannabis would "guarantee patients legal certainty and safe access to the medical use of cannabis", "limit the black market and guarantee product quality and correct labeling", "control points of sale and restrict access to this substance for minors".
The European Parliament's resolution in no way obliges the 28 member countries of the European Union to apply it to the letter, but the European institutions can now draw up EU-wide regulations and penalize countries that fail to comply with the standards in force.
Sources:
► Newsweed : https://bit.ly/2XmKrFu
► Cannabis Blog : https://bit.ly/2GL7q88
► Hospimedia : https://bit.ly/2EhtgMH
All of our articles are written by Vincent, a member of our team who is educated on the subject of cannabinoids and has a degree in Chemistry. The facts retranscribed through our information blog are taken from international scientific literature, whose sources are verifiable and quoted at the end of each of our articles.
All these data are the property of SWISS MEDICAL CANNABIS SA. It is protected by the 91/250/EEC and 96/9/EC directives, which grant copyright protection to computer programs and databases respectively. SWISS MEDICAL CANNABIS SA. reserves the right to take legal action against any copy or reproduction of our information. We also reserve the right to bring an action for damages, in accordance with Article L. 331-1-3 of the CPI, which states that "to determine the damages, the court shall take into consideration the negative economic consequences, including loss of earnings, suffered by the injured party, the profits made by the author of the infringement of rights and the moral prejudice caused to the owner of these rights as a result of the infringement.
Ping back: National Cancer Institute approves use of cannabinoids | Swiss Medical Cannabis SA
i'm hiv the only way to eat is thc the tri therapy screws up your liver your intestines no coment your sleep and inevitably your mind
it's high time things changed
in france we're 3 centuries behind the times
You're right, it's time for Europe to force states to experiment with cannabis.